Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, USA.
ACS Chem Neurosci. 2011 Aug 17;2(8):381. doi: 10.1021/cn200061g. Epub 2011 Jul 6.
STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA(B)) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209_ASD_P2b Trial_Initiation%206%2021%202011%20Final.pdf).
STX209（巴氯芬）是一种γ-氨基丁酸 B 型（GABA(B)) 受体激动剂，来自 Seaside Therapeutics，目前正在进行自闭症谱系障碍（ASD）的临床试验。该公司在 2010 年 9 月宣布的一项 2a 期试验取得积极结果后，启动了一项 2b 期研究(http://www.seasidetherapeutics.com/sites/default/files/STX209_ASD_P2b_Trial_Initiation_6_21_2011_Final.pdf)。
